Skip to main content
Quest Diagnostics

Analytical Validation of Blood-Derived Tumor Mutation Burden (bTMB) Assays: A Joint Consensus Recommendation of the BLOODPAC bTMB Analytical Validation Working Group

Analytical Validation of Blood-Derived Tumor Mutation Burden (bTMB) Assays: A Joint Consensus Recommendation of the BLOODPAC bTMB Analytical Validation Working Group

Authors: Baden J, Sausen M, Anfora AT, D'Auria KM, Dickey J, Godsey JH, Guan L, Lococo JS, Mansfield E, Meier KL, Merriam D, Pawloski T, Shukla S, Stetson D, Stewart MD, Wenz P, Leiman LC

Citation: J Mol Diagn. 2025 Oct;27(10):914-919. doi: 10.1016/j.jmoldx.2025.06.008

Specialties: Oncology, Immunology, Genetics

Related content

Publication
Skin Mutation Burden Drives Adaptive Immunity and Response to Immunotherapy
Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing
Test FAQ
Haystack MRD Testing
On-Demand Webinar
Prognostic Melanoma Molecular Testing to Inform Better Patient Care
Test FAQ
MelaNodal Predict
On-Demand Webinar
Precision Medicine: Your Role in Advancing the Future of Cancer Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.